Large Outflow of Money Witnessed in Juno Therapeutics, Inc.

Juno Therapeutics, Inc. (JUNO) During the most recent session, the shares traded at 0.14 points or 0.66% higher at $21.48. The money flow data is unimpressive with the net money flow value of $(-4.51) million. As per the intraday data, the upticks measured $5.49 million and the downticks measured $10 million. As a result, the up/down ratio registered a value of 0.55. The shares have seen 5.45% price change for the week.A block trade also made an entry with $0.31 million flowing in through upticks while $3.61 million flew out through downticks. The block tradeoff had the up/down ratio of 0.09. The net money flow for this big transaction was $(-3.3) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of Juno Therapeutics, Inc. rose by 6.76% in the last five trading days and 13.95% for the last 4 weeks. Juno Therapeutics, Inc. has dropped 11.57% during the last 3-month period . Year-to-Date the stock performance stands at 13.95%. Juno Therapeutics, Inc. (NASDAQ:JUNO) rose 0.66% or 0.14 points on Wednesday and made its way into the gainers of the day. After trading began at $21.51 the stock was seen hitting $21.84 as a peak level and $21 as the lowest level. The stock ended up at $21.48. The daily volume was measured at 1,986,089 shares. The 52-week high of the share price is $49.72 and the 52-week low is $17.52. The company has a market cap of $2,274 million.

Company has reported several Insider transactions to the SEC, on Nov 10, 2016, Robert Azelby (EVP & Chief Commercial Officer) sold 12,921 shares at 24.14 per share price.On Sep 29, 2016, Hans Edgar Bishop (CEO & President) sold 44,000 shares at 33.00 per share price.On Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at 40.71 per share price.

Juno Therapeutics Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.58. The company had revenue of $20.80 million for the quarter, compared to analysts expectations of $11.31 million. The companys revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Juno Therapeutics Inc was Downgraded by Raymond James to Mkt Perform on Dec 6, 2016. Juno Therapeutics Inc was Downgraded by SunTrust on Nov 25, 2016 to Hold, Lowers Price Target to $ 25 from a previous price target of $48 .Juno Therapeutics Inc was Downgraded by FBR & Co. on Nov 23, 2016 to Mkt Perform, Price Target of the shares are set at $30.Juno Therapeutics Inc was Reiterated by Maxim Group on Nov 23, 2016 to Buy, Lowers Price Target to $ 34 from a previous price target of $50 .

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.


Share this post

Leave a Reply